Recent Developments in the Chemotherapy of Chagas Disease

Author: Docampo, R.

Source: Current Pharmaceutical Design, Volume 7, Number 12, 1 August 2001 , pp. 1157-1164(8)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

Chagas disease remains an important health problem in the Americas. Advances are being made in parts of South America in blocking transmission from insect vectors or blood transfusion, but more effective chemotherapy is needed for the millions who are already infected. This is especially important since recent results have indicated that treatment is beneficial for the elimination of the chronic course of the disease. The rational development of new drugs depends on the identification of differences between human metabolism and that of the causative parasite, Trypanosoma cruzi. Recent developments in the study of the basic biochemistry of the parasite have allowed the identification of novel targets for chemotherapy, such as sterol metabolism, protein prenylation, proteases, and phospholipid metabolism, and these are the subject of this review.

Keywords: Chemotherapy; Chagas Disease; Trypanosoma cruzi; sterol metabolism; protein prenylation; proteases; phospholipid metabolism; isoprenoid biosynthesis; PROTEIN PRENYLATION; PROTEASES

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1381612013397546

Publication date: 2001-08-01

More about this publication?

Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.